OPKO Health Announces License for Topically Active Formulation of Ranibizumab
OPKO Health, Inc. (NYSE: OPK) today announced it has signed a research and license agreement with a prominent Mexican professor of ophthalmology for a topically active formulation of the anti-VEGF antibody, ranibizumab, utilizing OPKO proprietary drug delivery technology. The technology will initially target the development of the ranibizumab product to treat diabetic macular edema (DME), but the delivery system will also be studied with other pharmaceutical products to treat DME and other eye diseases.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.